iCAD, Inc. is a Delaware-registered company developing advanced AI-powered imaging solutions for cancer detection, diagnosis, and treatment, focusing on oncology and medical imaging technology.

# iCAD, Inc. Company Summary

**Business Overview:**  
iCAD, Inc. is a Delaware-registered company that specializes in the development and commercialization of advanced imaging and therapy solutions, primarily for cancer detection, diagnosis, and treatment. Its products leverage artificial intelligence (AI) and radiology imaging technologies to improve clinical workflows and patient outcomes.

**Key Details from the 10-K/A Filing:**  
- **Number of Employees:** The document does not specify the total number of employees.  
- **Number of Customers:** The report does not specify the exact number of customers or clients.  
- **Revenue and Income:** The financial data, including revenue and net income, is not included within the provided excerpt. The document states that no new financial statements are included in this filing, and the annual report references prior filings for financial data.

**Product and Market Focus:**  
- Development of AI-powered imaging solutions for radiology, including tools for cancer detection (notably breast and lung cancer).  
- Provides software and hardware used in medical imaging and diagnostics to healthcare providers.  
- Focuses on molecular pharmacology and clinical research related to advanced imaging applications in oncology.

**Corporate Structure and Governance:**  
- The company has a Board of Directors and several executive officers, including CEO Dana Brown.  
- The company has multiple committees overseeing risk management, audit, compensation, and governance.  
- As of April 18, 2025, the company had approximately 27.4 million shares outstanding.

**Financial and Regulatory Status:**  
- The company’s common stock is listed on NASDAQ under the symbol ICAD.  
- As of June 30, 2024, the market value of voting stock held by non-affiliates was approximately $32.56 million.

**Additional Details:**  
- The company is engaged in a pending merger with RadNet, Inc., expected to be completed in the second or third quarter of 2025.  
- The company’s filings focus on governance, risk management, executive compensation, and stockholder information rather than specific financials or operational performance metrics in this document.

**Note:**  
The provided excerpt is primarily regulatory, governance, and executive compensation information, with no detailed financial data or operational metrics such as revenue, profit, customer count, or employee totals.

iCAD, Inc. is a global leader in AI-powered cancer detection, focusing on breast cancer to enhance early detection and improve treatment outcomes using advanced technology.

# iCAD, Inc. Overview

iCAD, Inc. is a global leader in AI-powered cancer detection, specifically focusing on breast cancer. The company strives to enhance early detection and improve treatment outcomes by utilizing advanced technology in mammography and risk assessment.

### Key Products and Solutions

- **ProFound Breast Health Suite**: This suite includes several solutions for breast cancer detection, density assessment, cardiovascular risk evaluation, and personalized risk evaluation based on mammogram images.
    - **ProFound Detection**: AI-powered detection solution that improves accuracy in identifying suspicious lesions in mammograms.
    - **ProFound Density Assessment**: Standardizes breast density reporting based on mammographic images, which is crucial for identifying cancer risks.
    - **ProFound Risk**: A short-term risk assessment tool that predicts the likelihood of developing breast cancer within one or two years.
    - **ProFound Heart Health**: Evaluates breast arterial calcifications to assess cardiovascular risk from the same mammogram used for breast cancer screening.

### Market Presence

- **Global Reach**: iCAD's products are available in over 50 countries, and the company claims that its solutions have been utilized for more than 40 million mammograms worldwide in the last five years.
- **Customer Base**: iCAD has an active customer base of approximately 1,488 out of the 3,268 facilities implementing AI solutions in the U.S., which constitutes around 46% of the AI market and about 17% of the total U.S. mammography market.

### Financial Information

- **Revenue**: As of 2023, iCAD reported total revenue of approximately $4.9 million.
- **Net Loss**: The company incurred a net loss of approximately $4.9 million in 2023, leading to an accumulated deficit of about $272 million as of December 31, 2023.
- **Employees**: The company employs 69 individuals, with 67 being full-time. Staff distribution includes 24 in sales and marketing, 16 in research and development, and 12 in service, manufacturing, quality assurance, and operations.

### Strategic Initiatives

- iCAD is in a transition phase to a **SaaS (Software as a Service) / DaaS (Data as a Service)** model, which aims to provide its solutions in a more affordable, subscription-based format. This transition seeks to enhance revenue predictability while increasing accessibility for medical providers.
  
### Partnerships and Collaborations

- iCAD continues to expand its partnerships with organizations like **Google Health** to enhance its technologies and extend access to its products globally.

Overall, iCAD aims to create a world where cancer cannot hide by leveraging cutting-edge technology to facilitate early detection and improve healthcare outcomes.

ICAD INC

10-K / April 30, 2025

10-K / March 29, 2024

10-K / April 30, 2025

iCAD, Inc. Company Summary